Compare Cytokinetics Inc (CYTK) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Tapestry, Inc. — how do they compare? Cytokinetics Inc trades at $76.28 (market cap $10.63B), while Tapestry, Inc. trades at $153.5 (market cap $32.44B). The key difference: Tapestry, Inc. is far larger — about 3.1× Cytokinetics Inc's market cap, and Tapestry, Inc. pays a 1% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | TPR | |
|---|---|---|
Market Cap | $10.63B | $32.44B |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $164.78 |
52-Week Low | $34.31 | $95.69 |
Enterprise Value | $10.74B | $35.29B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
TPR trades at $164.78, up 1.49% with strong technical momentum and bullish moving averages. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $1.66 exceeding the $1.30 estimate. Analyst sentiment remains overwhelmingly positive with 31 buy ratings and a $190.33 consensus price target, representing 15.5% upside potential. Recent news highlights Tapestry's AI initiatives and strong brand momentum driving market share gains.
The outlook appears favorable given TPR's earnings beat streak and positive analyst coverage, though elevated valuation ratios (P/E 48.95, P/S 4.34) and recent net income margin compression from 12.23% to 2.61% warrant monitoring. Key risks include competitive pressures in luxury retail and potential macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
